OTCMKTS:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis $6.41 +4.99 (+351.41%) As of 09/25/2026 03:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Interpace Biosciences Stock (OTCMKTS:IDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$6.01▼$6.4350-Day Range$1.42▼$6.4152-Week Range$0.77▼$6.43Volume4,734 shsAverage Volume7,196 shsMarket Capitalization$28.40 millionP/E Ratio80.13Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences, Inc. is a molecular diagnostics company focused on providing testing and pathology services that support the diagnosis and management of cancer and other complex diseases. The company’s tests are designed to help physicians assess disease risk, improve diagnostic confidence and guide treatment decisions. Its portfolio has included molecular tests for thyroid nodules, pancreatic cysts and gastrointestinal conditions. Key offerings include ThyGeNEXT and ThyraMIR for evaluating thyroid nodules, as well as PancraGEN and PanDNA for assessing pancreatic cysts. These products combine molecular analysis with clinical and pathology information to help distinguish potentially serious disease from conditions that may be monitored more conservatively. Interpace serves physicians, hospitals, laboratories and other health-care providers primarily in the United States through its laboratory and commercial operations. The company previously operated under the PDI name before adopting the Interpace Biosciences identity as its business became centered on molecular diagnostics and personalized medicine.AI Generated. May Contain Errors. Read More Interpace Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreIDXG MarketRank™: Interpace Biosciences scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Interpace Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Interpace Biosciences is 80.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Interpace Biosciences is 80.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.27.Price to Book Value per Share RatioInterpace Biosciences has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Interpace Biosciences has been sold short.Short Interest Ratio / Days to CoverInterpace Biosciences has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Interpace Biosciences has recently decreased by 80.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterpace Biosciences does not currently pay a dividend.Dividend GrowthInterpace Biosciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Interpace Biosciences this week, compared to 2 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Interpace Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders0.93% of the stock of Interpace Biosciences is held by insiders.Percentage Held by Institutions5.73% of the stock of Interpace Biosciences is held by institutions.Read more about Interpace Biosciences' insider trading history. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesAspen Aerogels, Sezzle, PIMCO, Kimbell, Cytokinetics Insider MovesSeptember 26 at 9:11 AM | tipranks.comBorsa Istanbul Activates Circuit Breaker in TAPDI OKSIJEN’s TNZTP.E SharesSeptember 16, 2026 | tipranks.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 26 at 1:00 AM | TradeSmith (Ad)Circuit Breaker Halts Continuous Trading in TNZTP SharesSeptember 16, 2026 | tipranks.comCespira™, the Joint Venture between Westport and Volvo Group, reveals how HPDI™ 3.0 advances fuel economy and expands OEM optionsSeptember 14, 2026 | financialpost.comFPDI Gold Issues New Long-Dated Performance Rights Under Incentive SchemeSeptember 11, 2026 | tipranks.comPDO: Better Than PDI, Still Not Cheap EnoughSeptember 10, 2026 | seekingalpha.comPDI Gold Sets AGM Date and Deadline for Director NominationsSeptember 8, 2026 | tipranks.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How have IDXG shares performed this year? Interpace Biosciences' stock was trading at $1.2302 at the beginning of the year. Since then, IDXG stock has increased by 421.1% and is now trading at $6.41. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (OTCMKTS:IDXG) released its quarterly earnings data on Monday, August, 10th. The business services provider reported $0.01 earnings per share (EPS) for the quarter. The business services provider had revenue of $9.13 million for the quarter. Interpace Biosciences had a net margin of 67.64% and a trailing twelve-month return on equity of 145.40%. How do I buy shares of Interpace Biosciences? Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX). Company Calendar Last Earnings8/10/2026Today9/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolOTCMKTS:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.08 Trailing P/E Ratio80.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$24.58 million Net Margins67.64% Pretax Margin11.06% Return on Equity145.40% Return on Assets87.36% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$38.73 million Price / Sales0.73 Cash Flow$25.64 per share Price / Cash Flow0.25 Book Value$5.25 per share Price / Book1.22Miscellaneous Outstanding Shares4,430,000Free Float4,388,000Market Cap$28.40 million OptionableNot Optionable Beta0.61 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:IDXG) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored6 Elon Musk companies. The 1 FREE investor roadmap to them all.Elon Musk owns six companies, but most investors can only access four. Tesla, SpaceX, xAI, and X are public an...Zacks | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
